Is Laparoscopic Cholecystectomy a Safe Procedure for Patients Receiving Anticoagulant Therapy?

Wael Fathi Hasaniah  Metwalli Afifi El-Sayed  Hilal Al-Sayer
Talib Hashim Juma  Sabah Al-Hadeedi
Department of Surgery, Al-Amiri Hospital, Kuwait

Key Words
Laparoscopic cholecystectomy · Anticoagulant therapy · Atrial fibrillation

Abstract
Objective: To evaluate the safety of laparoscopic cholecystectomy (LC) in patients on oral anticoagulant therapy. Methods: Four patients were involved in this study on whom the procedure was performed in a conventional manner paying meticulous attention to haemostasis. The oral anticoagulant was resumed the night of the operation, and the patient was discharged and acceptable international normalised ratio was achieved postoperatively. Results: There was no thrombo-embolic or haemorrhagic complication. The mean hospital stay was 5 days. Conclusion: LC can be safely performed in patients on oral anticoagulant therapy.

Introduction
Laparoscopic cholecystectomy (LC) is now widely accepted as the procedure of choice for treating patients with benign gall bladder diseases. It has relatively few contraindications and is considered a safe procedure with low morbidity and mortality. It also has the advantage of reducing hospital stay compared to the open technique; therefore it is a more cost-effective procedure [1, 2].

As this procedure, unlike open cholecystectomy, involves the use of small wounds for the ports and hook diathermy for dissection, which might implicate a higher chance of bleeding, the question of safety arises when operating on patients taking oral anticoagulant therapy. Few reports in the literature [3, 4] suggest that proper control of the doses of anticoagulant in patients undergoing LC is not associated with increased morbidity related to anticoagulation. The aim of this study was to evaluate the morbidity of anticoagulants in patients undergoing LC and to revalidate its safety.

Patients and Methods
Four patients who were on chronic oral anticoagulant therapy underwent laparoscopic cholecystectomy during 1992–1997. (These patients were analysed as shown in table 1). The patients (3 females, 1 male) were between 38 and 75 years of age. They were all taking warfarin (coumarin) orally 4–6 mg daily, for periods of 18 months to 4 years. The patients were instructed to stop oral anticoagulants 2 days prior to operation.

On admission to the hospital each of the 4 patients was examined by a physician to evaluate their medical and cardiac status. A coagu-
Table 1. Clinical data

<table>
<thead>
<tr>
<th></th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operative time</td>
<td>60 min</td>
<td>68 min</td>
<td>60 min</td>
<td>100 min</td>
</tr>
<tr>
<td>Duration of anticoagulation</td>
<td>18 months</td>
<td>4 years</td>
<td>1 year</td>
<td>2 years</td>
</tr>
<tr>
<td>Indication for anticoagulation</td>
<td>aortic valve replacement</td>
<td>mitral and aortic valve replacement</td>
<td>chronic AF</td>
<td>mitral valve replacement</td>
</tr>
<tr>
<td>Dose of anticoagulant</td>
<td>5 mg</td>
<td>4 mg</td>
<td>6 mg</td>
<td>6 mg</td>
</tr>
<tr>
<td>Other medical diseases</td>
<td>DM</td>
<td>DM, HTN</td>
<td>HTN, IHD</td>
<td>none</td>
</tr>
<tr>
<td>Cardiac function</td>
<td>EF 63%</td>
<td>EF 68%</td>
<td>EF 66%</td>
<td>EF 65%</td>
</tr>
<tr>
<td>Indication for LC</td>
<td>CCC</td>
<td>CCC</td>
<td>CCC</td>
<td>CCC</td>
</tr>
<tr>
<td>Hospital stay</td>
<td>4 days</td>
<td>6 days</td>
<td>5 days</td>
<td>4 days</td>
</tr>
</tbody>
</table>

CCC = Chronic calcular cholecystitis; EF = ejection fraction; DM = diabetes mellitus; HTN = hypertension; AF = atrial fibrillation; MR = mitral regurge; IHD = ischaemic heart disease.

The average blood loss during the surgical procedure (LC) was approximately 50 ml and the operative time ranged from 60 to 100 min with an average of 72 min per procedure. A peroperative cholangiogram was not performed in these patients, and as there was no indication, drains were not used. None of the patients required blood transfusion and none of them developed any thromboembolic, haemorrhagic or cardiac complications. The hospital stay ranged from 4 to 6 days. All 4 patients with an INR between 2.0 and 2.5 were discharged on their usual dose of oral anticoagulant, and each was referred to the treating cardiologist for follow-up.

**Discussion**

Laparoscopic cholecystectomy has a risk of deep vein thrombosis reported in the literature between 1 and 1.5% [8–10]. Patients with prosthetic aortic or mitral valves, and patients with atrial fibrillation who are on long-term anticoagulants are at risk of thrombo-embolic and bleeding complications during and after surgery if their INR is not controlled pre- and perioperatively [11, 12].

Previously, it was thought that LC was hazardous in patients receiving oral anticoagulants. However, with wider experience and the improvement in pre- and postoperative care, surgery in patients taking anticoagulants is not contraindicated provided that the INR is kept between 1.5 and 2.0 at the time of operation [3]. Meticulous haemostasis using hook diathermy during the operation is mandatory to avoid complications.

**Conclusion**

Laparoscopic cholecystectomy is a safe procedure in patients taking oral anticoagulants provided that there is proper control to keep the INR in the range 1.5–2.0 during pre-, peri- and postoperative periods.
References